skip to main content columnskip to left navigationskip to horizontal navigation

Biomedical Sciences

Quillen College of Medicine

Qian Xie
Qian Xie

Qian  Xie 

Assistant Professor
Biomedical Sciences
Contact:

 

 

 

 

 

 

Additional Contact Information:


Department of BioMedical Sciences
Quillen College of Medicine

Stanton-Gerber Hall, Bldg.178
P.O. Box 70582
Office A026, Lab A021-022
Phone: 423-439-5332
Email:


EDUCATION/PROFESSIONAL EXPERIENCE

Postdoctoral Fellow,2006 Molecular Oncology, Van Andel Institute, Grand Rapids, MI, US

Ph.D., 2002 Fudan University Zhongshan Hospital, Shanghai, China. 

M.D., 1995 Fudan University Shanghai Medical College, Shanghai, China.

2015- Present    Assistant Professor, Department of Biomedical Sciences, East Tennessee State University, Johnson City, TN

2013-2015            Research Assistant Professor, Van Andel Research Institute, Grand Rapids, MI

2010-2013            Senior Research Scientist, Van Andel Research Institute, Grand Rapids, MI

2006-2010            Research Scientist, Van Andel Research Institute, Grand Rapids, MI   

RESEARCH/TEACHING INTERESTS

The success of molecular targeted therapy in cancer depends on knowledge of essential pathways that contribute to oncogenesis and the molecular targets that control pathway activity. The major research interest of my lab is to understand the role of MET signaling pathway in cancer, with primary focus on glioblastoma and hepatocellular carcinoma. We use both in vitro cell based assays and in vivo animal models to understand the molecular regulation of MET and Tyrosine Kinase signaling pathways in order to develop therapeutic strategies for cancer treatment. 

Research Projects:

1)      To determine the molecular mechanisms of MET-targeted therapy and the therapeutic combination strategies.
2)      To identify the underlying causes and treatments for glioblastoma.
3)      To develop preclinical animal modeling systems for studying tumor biology and therapeutics in glioblastoma.

SELECTED PUBLICATIONS

1.   Yuanzheng He, Jingjing Shi, Wei Yi, Xin Ren, Xiang Gao, Jianshuang Li, Nanyan Wu, Kevin Weaver, Qian Xie, Sok Kean Khoo, Tao Yang, Xiaozhu Huang, Karsten Melcher, and H. Eric Xu. Discovery of a highly potent glucocorticoid for asthma treatment. Cell Discovery, (1):15035, 2015. doi:10.1038/celldisc.2015.35

2.    Jennifer Johnson, Maria Libra Ascierto, Liang Kang, Robert Bradley, Sandeep Mittal, Michael Briggs, Kirk Tanner, Micheal E. Berens, Francesco M. Marincola,, George F. Vande Woude, and Qian Xie. Identifying HGF signature for MET-targeted therapy in glioblastoma. Journal of Translational Medicine, 17;13(1):306, 2015.

3.    Qian Xie*, Sandeep Mittal, and Michael E. Berens. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro-Oncology (16): 12, 1575-1584, 2014 [*Corresponding author]

4.    Qian Xie*, Yanli Su, Karl Dykema, Jennifer Johnson, Julie Koeman, Valeria De Giorgi, Alan Huang, Robert Schlegel, Curt Essenburg, Liang Kang, Keiichi Iwaya, Shuhji Seki, Sok Kean Khoo, Boheng Zhang, Franco M. Buonaguro, Francesco M. Marincola, Kyle Furge, George F. Vande Woude, and Nariyoshi Shinomiya*. Overexpression of HGF promotes HBV-Induced hepatocellular carcinoma progression and is an effective biomarker for Met-targeting therapy. Genes & Cancer, 4:247-60, 2013 [* Co- corresponding authors] Highlighted as Cover Story of the July/August issue

5.    Cui Y, Wu W, Zhou Y, Xie Q, Liu T, Jin J, Liu K. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxy geldanamycin. Future Oncology (3):411-8. 2013

6.    Xie, Q., Vande Woude, GF., Berens, ME. RTK inhibition: looking for the right pathways toward a miracle. Future Oncology (8):1397-1400, 2012 (Priority Review)

7.    Qian Xie*, Robert Bradley, Julie Koeman, Andrea Worschech, Liang Kang, Yanli Su, Lisa Kefene, Curt Essenburg, Dafna Kaufman, Tom DeKoning, Mark Enter, Timothy J. ORourke, Francesco M. Marincola, George F. Vande Woude*. HGF-autocrine activation in glioblastoma predicts the sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 10;109(2):570-5, 2012 [* Co-corresponding authors]

8.    Xie Q, Wondergem R., Shen YH, Cavey G, Ke JY, Thompson R, Bradley R, Daughtery-Holtrop J, Xu Y, Chen E, Omar H, Wenkert D, Xu, HE, and Vande Woude GF. 17AAG, through hydrophobic binding, targets mitochondrial VDAC and inhibits cell invasion. Proc Natl Acad Sci U S A. 108(10):4105-10, 2011

 

icon for left menu icon for right menu